Difference between revisions of "Team:Munich/HP/Gold Integrated/Doctors Without Borders"

Line 72: Line 72:
 
</tr>
 
</tr>
  
<p>
+
 
 
<i>Dr. De La Tour</i>: The fact is that we need ready to use devices with independently evaluated accuracy characteristics. In addition, technologies like those described in your publication should be useful to us only if they are usable in self-contained cartridges in a Point-of-Care instrument like the GeneXpert or the AlereQ.
 
<i>Dr. De La Tour</i>: The fact is that we need ready to use devices with independently evaluated accuracy characteristics. In addition, technologies like those described in your publication should be useful to us only if they are usable in self-contained cartridges in a Point-of-Care instrument like the GeneXpert or the AlereQ.
 
</p>
 
</p>

Revision as of 22:44, 29 October 2017


Dr. De La Tour: The fact is that we need ready to use devices with independently evaluated accuracy characteristics. In addition, technologies like those described in your publication should be useful to us only if they are usable in self-contained cartridges in a Point-of-Care instrument like the GeneXpert or the AlereQ.

Interview with Dr. De La Tour

Are you familiar with the term “synthetic biology"?

Dr. De La Tour: No, I have not heard of it.

Have you heard about the iGEM-Competition?

Dr. De La Tour: No, I do not.